{
    "doi": "https://doi.org/10.1182/blood.V120.21.4904.4904",
    "article_title": "Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers ",
    "article_date": "November 16, 2012",
    "session_type": "Molecular Pharmacology, Drug Resistance",
    "abstract_text": "Abstract 4904 Aim: We have previously presented HLA DRB1*13 and 11 tobe associated with response (IMMW, Paris, 2011). In this analysis we have expanded the sample size and have included Killer Immunoglobulin Receptor (KIR) ligands HLA A, Bw4 and C epitopes to further understand the mechanisms underlying this association. Patients and Methods: 115 patients diagnosed and treated in Ankara and Gazi University Hospitals and who have received a minimum of two months of Thalidomide ( T ), either alone or within a combination for the treatment of newly diagnosed or relapse myeloma were included. Treatment was given as either part of induction or consolidation: monotherapy (n= 54) or combination (n= 61), at a dose of median 100 mg (50\u2013600 mg) for a median of 7 months (2\u2013114 mo). Following consent HLA typing was done using Sequence-Specific Oligonucleotide primers. IMWG criteria was used for response assessment. Statistics were performed using the SPPS 15. 0 program. The most frequently observed three alleles at each loci and KIR ligands (C epitopes 1, 2 and Bw4) were evaluated to determine effects on response to T. Logistic regression analysis was used for univariateand multivariate analysis to evaluate the factors affecting response to thalidomide. Results: Fifty-two (45%) of the patients achieved at least PR. \u2265 PR and <PR responders were similar in respect to age, time from the diagnosis to initiation of thalidomide, gender, serum \u03b2 2 -microglobulin, albumin, LDH, and creatinin levels, paraprotein characteristics, bone marrow plasma cell ratio, presence of ASCT or allo-HCT, response to induction treatments except for the median number of chemotherapy lines prior to T use which was higher in the less responding group compared to \u2265 PR responders (p=0. 016). Comparison of these KIR ligand frequencies revealed HLA A*03, B*51, C*04 and DRB1*13 to be associated with response significantly (Tables). The frequency of A*03\u223cB*44\u223cDRB1*13, A*03\u223c DRB1*13 or A*03\u223c B*44, B*44\u223c DRB1*13 (contains \u2265 PR response associated specificities) patients responded frequently:1/1, 7/9, 4/5 or 3/3. Similarly A*11\u223cB*51\u223cC*04 or A*11\u223cB*51\u223cDRB1*11, A*11\u223cB*51 or B*51\u223cDRB1*11 (combining <PR response associated specificities) were not responding as well: 1/4, 0/2, 1/5 or 2/13. The OR for HLA A*03\u223cDRB1*13, B*51\u223cDRB1*11, B*51\u223cC*04, but not C*04 \u223cDRB1*11 showed a synergistic effect of the combination (Tables). Conclusion: Host related factors such as HLA DRB1 and KIR ligands are found to exert either inhibitory or activating effects on response to T. In addition to the number of previous lines of therapy, HLA, deserves to be included into the list of factors effecting response. Table 1: Comparison of HLA specificities among patients responding (\u2265PR) versus less/no response.  HLA . \u2265PR Response (n=52) . p value . <PR response (n=63) . HLA-A*02 24 (40%) 0.265 30 (60%) HLA-A*24 14 (42%) 0.836 19 (58%) HLA-A*03  20 (69%) 0.005  9 (31%) HLA-A*11 3 (21%) 0.084 11 (79%) HLA-B*35 14 (35%) 0.12 26 (65%) HLA-B*51  6 (22%) 0.008  21 (78%) HLA-B*44 12 (67%) 0.07 6 (33%) Bw4 42 (42%) 0.178 57 (58%) HLA-C*07 20 (59%) 0.429 20 (50%) HLA-C*04  12 (31%) 0.045  26 (69%) HLA-C*12 14 (56%) 0.253 11 (44%) C1 epitope 42 (50%) 0.058 42 (50%) C2 epitope 31 (42%) 0.404 43 (58%) HLA-DRB1*11 17 (37%) 0.121 29 (63%) HLA-DRB1*04 14 (50%) 0.827 14 (50%) HLA-DRB1*13 15 (65%) 0.059 8 (35%) HLA-DRB1*15 11 (61%) 0.202 7 (39%) HLA-A*03\u223cDRB1*13 7 (78%) 0.078 2 (22%) HLA-B*51 \u223cDRB1*11  2 (15%) 0.019  11 (85%) HLA-C*04 \u223cDRB1*11 7 (33%) 0.229 14 (67%) HLA-B*51 \u223cC*04  1 (11%) 0.04  8 (89%) HLA . \u2265PR Response (n=52) . p value . <PR response (n=63) . HLA-A*02 24 (40%) 0.265 30 (60%) HLA-A*24 14 (42%) 0.836 19 (58%) HLA-A*03  20 (69%) 0.005  9 (31%) HLA-A*11 3 (21%) 0.084 11 (79%) HLA-B*35 14 (35%) 0.12 26 (65%) HLA-B*51  6 (22%) 0.008  21 (78%) HLA-B*44 12 (67%) 0.07 6 (33%) Bw4 42 (42%) 0.178 57 (58%) HLA-C*07 20 (59%) 0.429 20 (50%) HLA-C*04  12 (31%) 0.045  26 (69%) HLA-C*12 14 (56%) 0.253 11 (44%) C1 epitope 42 (50%) 0.058 42 (50%) C2 epitope 31 (42%) 0.404 43 (58%) HLA-DRB1*11 17 (37%) 0.121 29 (63%) HLA-DRB1*04 14 (50%) 0.827 14 (50%) HLA-DRB1*13 15 (65%) 0.059 8 (35%) HLA-DRB1*15 11 (61%) 0.202 7 (39%) HLA-A*03\u223cDRB1*13 7 (78%) 0.078 2 (22%) HLA-B*51 \u223cDRB1*11  2 (15%) 0.019  11 (85%) HLA-C*04 \u223cDRB1*11 7 (33%) 0.229 14 (67%) HLA-B*51 \u223cC*04  1 (11%) 0.04  8 (89%) View Large Table 2: Univariate and multivariate analysis of risk factors  Variable . univariate . multivariate . P value . OR . 95% CI . P value . OR . 95% CI . Age 0.179 1.024 0.989\u20131.061 - - - Gender 0.623 1.206 0.573\u20132.538 - - - ISS       Stage I 0.573 1 - - - - Stage II 0.566 1.333 0.499\u20133.56    Stage III 0.299 1.697 0.625\u20134.606    The number of chemotherapy lines prior to thalidomide 0.043  0.681 0.469\u20130.988 0.037  0.598 0.37\u20130.97 HLA-A*03 0.004  3.75 1.525\u20139.224 0.004  5.75 1.74\u201319.04 HLA-A*11 0.069 0.289 0.076\u20131.1 - - - HLA-B*35 0.11 0.524 0.238\u20131.157 - - - HLA-B*44 0.053 2.85 0.987\u20138.23 0.021  5.56 1.3\u201323.76 HLA-B*51 0.008  0.261 0.096\u20130.708 0.005  0.16 0.046\u20130.57 HLA-C*04 0.043  0.423 0.184\u20130.971 0.017  0.27 0.094\u20130.79 HLA-DRB1*13 0.046  2.656 1.019\u20136.925 0.318 1.86 0.55\u20136.31 HLA-DRB1*11 0.095 0.517 0.238\u20131.122 - - - HLAA*03\u223cDRB1*13 0.067 4.53 0.897\u201322.91 - - - HLAB*51\u223cDRB1*11 0.03 0.178 0.037\u20130.846 - - - Variable . univariate . multivariate . P value . OR . 95% CI . P value . OR . 95% CI . Age 0.179 1.024 0.989\u20131.061 - - - Gender 0.623 1.206 0.573\u20132.538 - - - ISS       Stage I 0.573 1 - - - - Stage II 0.566 1.333 0.499\u20133.56    Stage III 0.299 1.697 0.625\u20134.606    The number of chemotherapy lines prior to thalidomide 0.043  0.681 0.469\u20130.988 0.037  0.598 0.37\u20130.97 HLA-A*03 0.004  3.75 1.525\u20139.224 0.004  5.75 1.74\u201319.04 HLA-A*11 0.069 0.289 0.076\u20131.1 - - - HLA-B*35 0.11 0.524 0.238\u20131.157 - - - HLA-B*44 0.053 2.85 0.987\u20138.23 0.021  5.56 1.3\u201323.76 HLA-B*51 0.008  0.261 0.096\u20130.708 0.005  0.16 0.046\u20130.57 HLA-C*04 0.043  0.423 0.184\u20130.971 0.017  0.27 0.094\u20130.79 HLA-DRB1*13 0.046  2.656 1.019\u20136.925 0.318 1.86 0.55\u20136.31 HLA-DRB1*11 0.095 0.517 0.238\u20131.122 - - - HLAA*03\u223cDRB1*13 0.067 4.53 0.897\u201322.91 - - - HLAB*51\u223cDRB1*11 0.03 0.178 0.037\u20130.846 - - - CI: Confidence interval; HLA: Human leukocyte antigen; OR: Odds ratio. View Large Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "human leukocyte antigens",
        "immunoglobulins",
        "ligands",
        "multiple myeloma",
        "thalidomide",
        "turkish",
        "hla-b antigens",
        "hla-a antigens",
        "hla-a2 antigen",
        "hla-c antigens"
    ],
    "author_names": [
        "Elif Suyani, MD",
        "Sule Mine Bakanay, MD",
        "Klara Dalva, MD",
        "Ezgi Cakmak, MSc",
        "Rauf Haznedar, MD",
        "Gulsan Sucak, MD",
        "Meral Beksac, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Elif Suyani, MD",
            "author_affiliations": [
                "Hematology, Gazi University School of Medicine, Ankara, Turkey, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Sule Mine Bakanay, MD",
            "author_affiliations": [
                "Hematology, Ataturk Egitim ve Arastirma Hastanesi, Ankara, Turkey, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Klara Dalva, MD",
            "author_affiliations": [
                "Hematology, Ankara University School of Medicine, Ankara, Turkey"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ezgi Cakmak, MSc",
            "author_affiliations": [
                "Hematology, Ankara University School of Medicine, Ankara, Turkey"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rauf Haznedar, MD",
            "author_affiliations": [
                "Hematology, Gazi University School of Medicine, Ankara, Turkey, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gulsan Sucak, MD",
            "author_affiliations": [
                "Hematology, Gazi University School of Medicine, Ankara, Turkey, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Meral Beksac, MD",
            "author_affiliations": [
                "Hematology, Ankara University School of Medicine, Ankara, Turkey"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-23T04:08:45",
    "is_scraped": "1"
}